Aphria and Tilray’s Combined European Footprint Will Give

New Post Public Reply Private Reply Replies (0) Message Board
toodles
236
Aphria and Tilray’s Combined European Footprint Will Give Them A Massive Advantage Over The Incoming Competition
EDITORIAL Mar 29, 2021 • 7:31 AM EDT

3 MIN READ • BY MICHAEL BERGER
SHARE Share - Facebook Share - Twitter
During the last year, we have noticed a transformational change with the legal cannabis sector and noticed that Canadian Licensed Producers (LPs) were becoming highly focused on the cannabis opportunity in the European Union (EU) and the United States (US).

Last week, we highlighted a few leading Canadian LPs that have leverage to the US market and received a few questions about the companies that are leading the legal cannabis movement in the EU. Today, we highlighted some of the Canadian LPs that are considered to be leaders in EU and provided an update on how we think this aspect of the industry could advance.

Aphria and Tilray are Positioned to be Leaders in the EU

For several years, Aphria Inc. (APHA.TO) (APHA) has been highly focused on the EU cannabis opportunity and has an impressive distribution business with a large footprint in Germany. After the Canadian LP reported to have entered into a definitive agreement to merger with Tilray Inc. (TLRY), we conducted in-depth analysis on the EU assets that would be owned by the combined company.

From cultivation to distribution, the combined company is expected to be the largest cannabis business in the EU. Tilray provides strategic assets to the combined company and owns an EU good manufacturing practice (EU-GMP) facility in Portugal. Since the facility was constructed to meet EU GMP standards, the company will be able to export cannabis to strategic markets across the globe (where legislation permits it).

Cronos has Been Slow to Execute on the International Market

Cronos Group (CRON.TO) (CRON) has been quietly capitalizing on the EU cannabis market and is a Canadian LP that has been flying under the radar. We believe the company has attractive leverage to burgeoning international markets and will be monitoring how the story advances in 2021 and beyond.

Cronos is executing on a multi-faceted growth strategy and operates a global network, with partnerships, production and distribution across five continents. Through a joint venture with Kibbutz Gan Shmuel, a commercial kibbutz and food company, Cronos could export cannabis that was cultivated in Israel to the EU.

We expect Cronos to make the cannabis opportunity in the EU a major focus of the business in the near future and will monitor this aspect of the story. The company has a strong balance sheet and we attribute this to Altria’s $1+ billion investment in it. Going forward, Cronos has the resources that are needed to capitalize on the EU and will continue to closely monitor the story.

Canopy Growth Divests of Non-EU International Cannabis Assets

Last year, Canopy Growth Corporation (WEED.TO) (CGC) went through a major transition that was centered around closing facilities and lowering expenses. After receiving more than $4 billion from Constellation Brands (STZ), the leading Canadian LP started announcing a series of large investments and acquisitions.

A few years later, Canopy Growth lowered its exposure to certain international markets and divested of several assets. The move resulted in the Canadian cannabis company ceasing certain operations in Africa, Canada, Colombia and the US in an effort to improve efficiencies in its global operations.

When Canopy Growth announced that it was scaling down its international cannabis footprint, it announced that the downsizing would not affect Europe. We find this be of significance and consider it to be a testament to the strength of the EU cannabis opportunity.

If you are interested in learning about additional companies that are levered to the emerging international markets, please send an email to support@technical420 to be added to our distribution list.

Share Share - Facebook Share - Twitter
Tags
APHAAPHRIA INC.CRONCRONOS GROUPEU CANNABIS STOCKSEUROPEAN CANNABISTILRAYTLRY

AUTHORED BY
Michael Berger
Michael Berger is Managing Partner of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

TOODLES
Scroll down for more posts ▼

Top 10 Most Recent News Articles

NARUTO Card Game Set for June 2027 Global Launch

Updated Category News Views 14

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 13

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 14

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 9

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 14

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 15

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 14

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 11

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 8

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Telehealth Trends: A Comprehensive Yearly Insight

Updated Category News Views 346

FAIR Health's Telehealth Tracker: A Milestone Year FAIR Health has reached a significant milestone with its Monthly Telehealth Regional Tracker entering its sixth year. This tracker provides valuable insights into how telehealth usage has evolved, empowering stakeholders to understand trends in healthcare delivery. New Features and Data Insights The latest iteration of...

Continue Reading
Exploring Analog Devices: A $1000 Investment Journey

Updated Category News Views 139

The Growth of Analog Devices Inc (NASDAQ: ADI) Investors have increasingly turned their attention to Analog Devices Inc, a leader in the semiconductor industry. Over the last five years, Analog Devices has consistently outperformed the market, showcasing an annualized return of 16.0%. With a current market capitalization standing at an impressive $119.42 billion, the...

Continue Reading
Celebrating Excellence in Clinical Simulation: Meet the Nominees

Updated Category News Views 110

Highlighting Excellence in Clinical Simulation Awards A Representation of the Best in Simulation Healthcare Education in 2024 Education Management Solutions (EMS), a frontrunner in healthcare simulation and competency management platforms, has proudly announced its nominees for the 16th Annual Excellence in Clinical Simulation Awards. Each year, this noteworthy event...

Continue Reading
Significant Oil Price Drop Benefits Airlines and Cruise Lines

Updated Category News Views 195

Oil Prices Experience a Significant Drop Amid Easing Tensions Oil prices witnessed a noticeable decrease recently, plummeting over 5% during early trading in New York. This shift came as geopolitical tensions in the Middle East appeared to stabilize after an assurance from Israeli Prime Minister Benjamin Netanyahu that Iran’s oil facilities would not be targets in any...

Continue Reading
RxSight, Inc. Faces Legal Challenges: Investors Invited to Join Lawsuit

Updated Category News Views 136

RxSight, Inc. Investors Invited to Participate in Class Action Lawsuit Investors of RxSight, Inc. are becoming aware of significant opportunities to engage in a class action lawsuit. This legal action is being initiated by Bronstein, Gewirtz & Grossman, LLC, a law firm with a national reputation for advocating on behalf of investors. They are notifying shareholders that...

Continue Reading